Literature DB >> 224763

Detection of complement-dependent lytic antibodies in sera from bovine leukemia virus-infected animals.

D Portetelle, C Bruck, A Burny, D Dekegel, M Mammerickx, J Urbain.   

Abstract

Cattle and sheep infected by Bovine Leukemia Virus (BLV) harbor complement-dependent cytotoxic IgG1 antibodies. These antibodies lyse BLV producing cells but are inactive against noncultured tumorous lymphocytes of animals with persistent lymphocytosis. The target structure in the cell membrane contains antigenic determinants of BLV gp 60. The level of cytotoxic activity increases with progression of the disease towards the tumor phase. Sheep vaccinated with inactivated BLV have no cytotoxic activity in the serum but seem to resist infectious BLV challenge. Such cytotoxic activities do not protect the host against tumor growth but strongly control viremia and thus limit BLV spread within bovine and ovine populations.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 224763

Source DB:  PubMed          Journal:  Ann Rech Vet        ISSN: 0003-4193


  8 in total

1.  Bovine leukemia virus transcription is controlled by a virus-encoded trans-acting factor and by cis-acting response elements.

Authors:  D Derse
Journal:  J Virol       Date:  1987-08       Impact factor: 5.103

2.  Role of the 3' long open reading frame region of bovine leukemia virus in the maintenance of cell transformation.

Authors:  R Kettmann; Y Cleuter; D Gregoire; A Burny
Journal:  J Virol       Date:  1985-06       Impact factor: 5.103

3.  Polyclonal bovine sera but not virus-neutralizing monoclonal antibodies block bovine leukemia virus (BLV) gp51 binding to recombinant BLV receptor BLVRcp1.

Authors:  O Orlik; J Ban; J Hlavaty; C Altaner; R Kettmann; D Portetelle; G A Splitter
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

4.  Protection of sheep against bovine leukemia virus (BLV) infection by vaccination with recombinant vaccinia viruses expressing BLV envelope glycoproteins: correlation of protection with CD4 T-cell response to gp51 peptide 51-70.

Authors:  M H Gatei; H M Naif; S Kumar; D B Boyle; R C Daniel; M F Good; M F Lavin
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

5.  Cytotoxic antibody in cattle and sheep exposed to bovine leukemia virus.

Authors:  T Honma; M Onuma; M Suneya; T Mikami; H Izawa
Journal:  Arch Virol       Date:  1980       Impact factor: 2.574

6.  Genomic integration of bovine leukemia provirus: comparison of persistent lymphocytosis with lymph node tumor form of enzootic.

Authors:  R Kettmann; Y Cleuter; M Mammerickx; M Meunier-Rotival; G Bernardi; A Burny; H Chantrenne
Journal:  Proc Natl Acad Sci U S A       Date:  1980-05       Impact factor: 11.205

7.  Inhibition of protein kinase C results in decreased expression of bovine leukemia virus.

Authors:  W A Jensen; B J Wicks-Beard; G L Cockerell
Journal:  J Virol       Date:  1992-07       Impact factor: 5.103

Review 8.  Mechanisms of leukemogenesis induced by bovine leukemia virus: prospects for novel anti-retroviral therapies in human.

Authors:  Nicolas Gillet; Arnaud Florins; Mathieu Boxus; Catherine Burteau; Annamaria Nigro; Fabian Vandermeers; Hervé Balon; Amel-Baya Bouzar; Julien Defoiche; Arsène Burny; Michal Reichert; Richard Kettmann; Luc Willems
Journal:  Retrovirology       Date:  2007-03-16       Impact factor: 4.602

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.